首页> 美国卫生研究院文献>Therapeutic Advances in Vaccines >Plant-based vaccines for animals and humans: recent advances in technology and clinical trials
【2h】

Plant-based vaccines for animals and humans: recent advances in technology and clinical trials

机译:动植物疫苗:技术和临床试验的最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.
机译:自从第一台工厂工程技术成立以来,已有30年的历史了。尽管基于植物的药物或疫苗的概念促使我们使用植物工程技术开发实用的商业产品,但要达到最终目标仍存在一些困难:制造经批准的产品。目前,美国农业部批准的唯一一种植物疫苗是在悬浮培养的烟草细胞中生产的用于家禽的新城疫疫苗。基于植物的疫苗商业化的进展需要大量的努力和时间,但是用于人类和动物的几种候选疫苗正在临床试验中。这篇综述讨论了与植物疫苗开发有关的植物工程技术和法规,并概述了目前正在临床试验中的人和动物疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号